Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Patrick Schloemer's publication output changed over time?
ScholarIQpublication output · 2013–2026
Output grew0% over the shown period — from 1 works in 2013 to 1 in 2026.
1
1
2
2
4
1
201320192020202320242026
What are the most-cited papers on Patrick Schloemer?
ScholarIQmost cited works
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos
New England Journal of Medicine. 20202,761 CitationsOPEN ACCESS
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph, George L. Bakris, For the FIDELIO-DKD Investigators
Circulation. 2020289 CitationsOPEN ACCESS
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Christina Nowack, Peter Kolkhof, Anna Carolina Galvão Ferreira, Patrick Schloemer, Gerasimos Filippatos, on behalf of the FIDELIO-DKD study investigators
American Journal of Nephrology. 2019181 CitationsOPEN ACCESS
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund, Alasdair D Henderson, Meike Brinker, Peter Kolkhof, Patrick Schloemer, James Lay‐Flurrie, Prabhakar Viswanathan, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Peter Rossing, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon
Nature Medicine. 2024135 CitationsOPEN ACCESS
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial
Muthiah Vaduganathan, Brian Claggett, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faı̈ez Zannad, Akshay S. Desai, Pardeep S. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay‐Flurrie, John J.V. McMurray, Scott D. Solomon
European Journal of Heart Failure. 202484 CitationsOPEN ACCESS
Related on ScholarIQ
FIND
Institution
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Paper
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Paper
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
Paper
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Paper
Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial
Paper